[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.188.59. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 517
Citations 0
News From the Food and Drug Administration
July 5, 2016

Implant for Opioid Dependence

JAMA. 2016;316(1):24. doi:10.1001/jama.2016.8067

The first buprenorphine implant for maintenance treatment of opioid dependence has received FDA approval (http://1.usa.gov/1RuiaRi).

Previously, buprenorphine was approved for opioid dependence as a pill or film placed under the tongue or on the inside of the cheek until it dissolves. The pills and films are effective but can be lost, forgotten, or stolen. The 6-month implant may improve adherence for many people in recovery. It is intended for patients with prolonged clinical stability at a daily dose of 8 mg or less of oral buprenorphine.

First Page Preview View Large
First page PDF preview
First page PDF preview
×